Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Joyce Stellabott

Yanfeng Zhang

Robert S Meissner

James J Perkins

Lushi Tan

Aaron S Cote

Wenjie Li

Ian Mangion

Alfred Lee

Yuan-Hon Kiang

Michael J McNevin

Benjamin D Sherry

Kung-I Feng

Yong Liu

Ryan Cohen

Scott Schultz

Gary Martin

The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.

Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Polymorphs of an androgen receptor modulator

Growing community of inventors

Perkasie, PA, United States of America

Joyce Stellabott